Association of Hyperautofluorescence Signals with Geographic Atrophy Progression in the METformin for the MINimization of Geographic Atrophy Progression Trial
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Jasmeet Saroya (ORCID: https://orcid.org/0009-0008-8064-774X)
- Noor Chahal (ORCID: https://orcid.org/0009-0006-1718-8419)
- Antonio Maieli Diaz
- Sina Farsiu (ORCID: https://orcid.org/0000-0003-4872-2902)
- Glenn Yiu (ORCID: https://orcid.org/0000-0003-3061-3310)
- Jay M. Stewart (ORCID: https://orcid.org/0000-0003-1054-3423)
- Michael J. Allingham
- Liangbo L. Shen (ORCID: https://orcid.org/0000-0002-1823-0854)
- Jeremy D. Keenan (ORCID: https://orcid.org/0000-0002-7118-1457)
- Abu Tahir Taha
- Mengyuan Sun (ORCID: https://orcid.org/0000-0003-2309-5172)
Institutions
- San Francisco General Hospital (US)
- Gladstone Institutes (US)
- Duke University (US)
- University of California, San Francisco (US)
- San Francisco Foundation (US)
- Duke Medical Center (US)
- University of California, Davis (US)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2024-09-12
- DOI
- https://doi.org/10.1016/j.xops.2024.100620
- Citations
- 4
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.15
Funders
- Research to Prevent Blindness
- NGM Biopharmaceuticals
- Carl Zeiss Meditec AG
- National Institutes of Health
- University of California, Davis
- University of California, San Francisco